Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) Insider Sells 5,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 5,000 shares of the business’s stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $19.62, for a total value of $98,100.00. Following the completion of the transaction, the insider owned 947,688 shares in the company, valued at $18,593,638.56. The trade was a 0.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Enliven Therapeutics Trading Up 0.9%

NASDAQ:ELVN opened at $19.84 on Friday. The stock has a 50-day moving average price of $20.63 and a 200 day moving average price of $19.87. The stock has a market capitalization of $1.18 billion, a P/E ratio of -9.92 and a beta of 0.93. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. On average, research analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC boosted its holdings in shares of Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after purchasing an additional 1,114 shares during the period. GAMMA Investing LLC lifted its position in Enliven Therapeutics by 3,058.1% in the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock worth $53,000 after buying an additional 2,630 shares during the last quarter. Quantbot Technologies LP purchased a new position in Enliven Therapeutics during the first quarter worth $60,000. BNP Paribas Financial Markets increased its position in Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Enliven Therapeutics by 194.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after acquiring an additional 3,490 shares during the period. 95.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ELVN. The Goldman Sachs Group assumed coverage on Enliven Therapeutics in a research report on Monday, June 16th. They set a “buy” rating and a $37.00 price objective for the company. Jones Trading reduced their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a research note on Friday, May 16th. Robert W. Baird increased their target price on Enliven Therapeutics from $40.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, June 16th. Finally, HC Wainwright boosted their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, July 2nd. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $41.20.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.